Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(25%)
Terminated
1(25%)

Phase Distribution

Ph phase_2
3
75%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(2)

Detailed Status

Active, not recruiting1
Terminated1
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (75.0%)
Phase 41 (25.0%)

Trials by Status

active_not_recruiting125%
terminated125%
withdrawn125%
not_yet_recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
not_yet_recruitingphase_4

Tirzepatide in Idiopathic Intracranial Hypertension Trial

NCT07191873
active_not_recruitingphase_2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728
withdrawnphase_2

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

NCT06901349
terminatedphase_2

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

NCT06515418

Clinical Trials (4)

Showing 4 of 4 trials
NCT07191873Phase 4

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Not Yet Recruiting
NCT06643728Phase 2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Active Not Recruiting
NCT06901349Phase 2

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Withdrawn
NCT06515418Phase 2

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4